Cartesian Therapeutics, Inc. — Director's Dealing 2025

Jan 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2025-01-02

Reporting Person: DeSilva Nishan M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-02	Common Stock	A	2600	—	Acquired	8766	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-02	Stock Option (Right to Buy)	$16.93	A	7800	Acquired	2035-01-01	Common Stock (7800)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$19.656	2034-01-01	Common Stock (7600)	7600	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.

F2: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F3: This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.